Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

What is a 'failure' of bisphosphonate therapy for osteoporosis?

Carey JJ.

Cleve Clin J Med. 2005 Nov;72(11):1033-9. Review.

PMID:
16315442
2.

Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.

Cramer JA, Silverman S.

Am J Med. 2006 Apr;119(4 Suppl 1):S12-7. Review.

PMID:
16563936
3.

Improving compliance and persistence with bisphosphonate therapy for osteoporosis.

Emkey RD, Ettinger M.

Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. Review.

PMID:
16563937
4.

[Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].

Nishida A, Ito M.

Clin Calcium. 2011 Jan;21(1):120-3. doi: CliCa1101120123. Review. Japanese.

PMID:
21187605
5.
6.

Compliance and persistence with osteoporosis therapies.

Silverman SL, Gold DT.

Curr Rheumatol Rep. 2008 Apr;10(2):118-22. Review.

PMID:
18460266
7.

Intravenous zoledronic acid for the treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2008 Mar;6(1):17-23. Review.

PMID:
18430396
8.

[Bisphosphonate therapy for osteoporosis and bone strength].

Kishimoto H.

Clin Calcium. 2006 Sep;16(9):1513-19. Review. Japanese.

PMID:
16951477
9.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
10.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
11.

[The successful development of bisphosphonates in the therapy of osteoporosis].

Fassbender WJ, Stumpf UC, Kurth A.

Med Klin (Munich). 2006 Jun;101 Suppl 1:6-14. German.

PMID:
16826363
12.

[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].

Fukunaga M.

Clin Calcium. 2009 Jan;19(1):63-73. doi: CliCa09016373. Review. Japanese.

PMID:
19122266
13.

[Bisphosphonate treatment of osteoporosis and other skeletal diseases].

Syversen U, Halse JI.

Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):244-7. doi: 10.4045/tidsskr.09.0470. Review. Norwegian.

14.

Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.

Reginster JY, Malaise O, Neuprez A, Jouret VE, Close P.

Drugs Aging. 2007;24(5):351-9. Review.

15.

[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].

Asano S, Suzuki A, Itoh M.

Clin Calcium. 2009 Aug;19(8):1179-85. doi: CliCa090811791185. Review. Japanese.

PMID:
19638702
16.

Adherence and persistence: impact on outcomes and health care resources.

Reginster JY.

Bone. 2006 Feb;38(2 Suppl 2):S18-21. Epub 2006 Jan 27. Review.

PMID:
16443406
17.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
18.

Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.

Gold DT, Bonnick SL, Amonkar MM, Kamel HK, Agarwal S, Zaidi M.

Gend Med. 2008 Dec;5(4):374-84. doi: 10.1016/j.genm.2008.10.004.

PMID:
19108810
19.

How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.

Gold DT, Alexander IM, Ettinger MP.

Ann Pharmacother. 2006 Jun;40(6):1143-50. Epub 2006 May 30. Review.

PMID:
16735667
20.

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

Rabenda V, Hiligsmann M, Reginster JY.

Expert Opin Pharmacother. 2009 Oct;10(14):2303-15. doi: 10.1517/14656560903140533. Review.

PMID:
19640210

Supplemental Content

Support Center